Collobaration with COH on FTO while retaining a decent share of...

Collobaration with COH on FTO while retaining a decent share of the IP will be expensive.
Even if the two EMD AML trials are scrapped, there won't be enough cash.

Some people think that RAC is going to raise cash soon from a cardioprotection partnership. While this could be done soon, it would be suboptimal to enter into a partnership before we have any P2 cardioprotection results.

So there's a funding gap.
It will require a CR.
Due to the inevitable discontent about a CR from people who are unrealistically expecting to retire in the near future on their RAC holding rather than being asked to stump up again so soon after the Dec 2021 raise, I exoect that the CR will need to be accompanied by a sweetener issue of bonus options.

This competition is to guess the strike price of tbose sweetener options.

My guess is $2.50, because:
* that's higher than the SP has been for some time, but it's achievable on good news
* the strike price needs to be less than $3.00 because holders are sick of subscribing at $3 00

(There's a separate thread to guess the date of the CR)